What ALVALIN Treats: Main Uses and Benefits

ALVALIN is generally used in clinical settings as a supportive treatment for diet-related obesity, specifically targeting adult patients whose condition is characterized by a high degree of difficulty adhering to necessary caloric restrictions. The substance is considered relevant as an adjunct therapy for patients with a high Body Mass Index.

The medication plays a role in managing symptoms related to uncontrolled caloric intake and is commonly used to help with managing symptoms that interfere with daily comfort related to appetite. Its therapeutic focus is to support adherence to a reduced-calorie diet, which is relevant in conditions where symptoms may intensify temporarily. This assistance helps ease the overall symptom burden associated with intense hunger and contributes to improved comfort.

Its scope is considered relevant for the symptomatic management of excessive hunger signals, providing support within a multidisciplinary weight loss programme, and may assist with the management of measurable clinical goals, such as a reduction in Body Mass Index (BMI).

“This assistance supports the patient during difficult episodes by easing distress and contributing to improved comfort during periods of heightened appetite.”

---

Quick Fact: Support for Symptoms of Excessive Hunger

---

This medication is considered relevant in therapeutic contexts where functional stability becomes affected, and when assistance is required to support measurable clinical goals. The management of these therapeutic goals may assist with maintaining functional stability and supports general well-being through its use in conditions involving systemic imbalance.

Eligibility Map: Who can and cannot use ALVALIN

This section outlines the official eligibility and non-eligibility information for ALVALIN (aliskiren) based on governmental regulatory documents, focusing strictly on contraindications and restricted use.

---

Official Eligibility Scope

Category	Eligibility Status (Regulatory)
Populations for Allowed Use	Patients with hypertension (high blood pressure)
Populations with Restricted Use	Patients with moderate to severe renal impairment (GFR < 60 mL/min) who are taking an ACE inhibitor or ARB.
Populations for Contraindicated Use	Patients with diabetes who are taking an ACE inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).
Age-Related Rules	Contraindicated in pediatric patients under 2 years of age.
Clinical States for Contraindication	Known hypersensitivity to aliskiren or any component of the formulation.

---

Official Eligibility Statements

• Concomitant use with Angiotensin Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) is strictly prohibited (contraindicated) in patients with diabetes due to an increased risk of renal impairment, hyperkalemia (high potassium), and hypotension (low blood pressure).
• The use of ALVALIN in combination with an ACEI or ARB should be avoided in patients with moderate to severe renal impairment (Glomerular Filtration Rate [GFR] < 60 mL/min). This restriction is in place due to the risk of severe renal dysfunction, hyperkalemia, and low blood pressure.
• ALVALIN must be discontinued as soon as possible if pregnancy is detected due to the risk of fetal injury and death.

Summary of Eligibility Profile

Regulatory documents primarily define eligibility for ALVALIN through its use in managing hypertension, while imposing severe restrictions on combination therapy. The official labeling emphasizes that the medicine is strictly contraindicated for patients with diabetes who are simultaneously using ARBs or ACEIs, a key eligibility constraint linked to patient safety and specific comorbidities. Use is also formally discouraged in individuals with moderate to severe kidney function impairment when using these combination drugs.

The official regulatory profile for ALVALIN (Cathine) defines its interaction characteristics based on its classification as an indirectly acting sympathomimetic amine. This structure results in explicit prohibitions, timing requirements, and documented risks of pharmacodynamic potentiation or opposition, all of which are documented in government prescribing information.

Formal Interaction-Related Restrictions

The co-administration of ALVALIN with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated by regulatory agencies due to the significant potential for severe pressor reactions, including hypertensive crisis. To manage this critical risk, a mandatory separation window of at least 14 days is required between the discontinuation of MAOI therapy and the initiation of Cathine treatment.

Documented Pharmacodynamic Effects

Interaction with other medicinal products is common due to the pressor activity of Cathine:

• Blood Pressure Modulation: Co-administration with other sympathomimetic agents (including certain decongestants), Tricyclic Antidepressants, or Ergot Alkaloids may potentiate effects, potentially leading to an increase in blood pressure.
• Antagonism: ALVALIN may formally antagonize the therapeutic effect of certain antihypertensive drugs, such as beta-blockers, by opposing their hypotensive action.
• Anaesthesia Risk: Concurrent use with Halogenated Anaesthetic Agents is documented as potentially provoking or worsening ventricular arrhythmias.

Absorption Rate Interactions

Interactions with non-medicinal products that affect absorption are also documented. Antacids may increase the rate of Cathine uptake, whereas Kaolin may decrease the rate of absorption.

Modulation of Monoamine Neurotransmitter Pathways

ALVALIN exerts its mechanistic effect through indirect sympathomimetic activity, specifically influencing the monoamine neurotransmitter system, particularly norepinephrine (NE) and dopamine (DA). The active component modulates the presynaptic release and inhibits the reuptake of these mediators in the synaptic cleft, thereby increasing their functional availability and altering the intensity of signaling across central and peripheral neural pathways.

Targeted Central Pathway Adjustment

This resultant increase in monoamine activity is concentrated in central neural pathways, specifically key areas of the hypothalamus, which contains the signaling centers relevant to feeding behavior and energy homeostasis. This targeted mechanism acts to modulate excessive signaling within the hypothalamic pathways that govern appetite regulation. By engaging these receptor-mediated cascades, the drug modifies the early molecular steps that influence the dynamics of signaling, which results in the adjustment of activity within targeted monoaminergic systems and shapes the resulting physiological modulation.

Official Administration Guidelines

ALVALIN (Cathine hydrochloride) is provided as an oral solution and is administered exclusively via the oral route. The official instructions for its use define the precise regimen, including dosing, frequency, and treatment duration, which must be followed as part of a structured program for weight management.

Instruction	Detail
Route of administration:	Oral route only (liquid drops).
Dosing schedule:	The daily dose is determined individually by the prescriber, typically starting at a low level and ranging up to a maximum of 53.3 mg of Cathine hydrochloride.
Frequency and Timing:	Once daily administration, specified for the morning to align with the intended daily use pattern.
Course Duration:	The treatment is strictly limited to short-term use, with a total course of therapy not exceeding 24 weeks (six months).
Contextual Condition:	Must be used only as an adjunct to a comprehensive, medically supervised, reduced-calorie diet and lifestyle modification program.

The official use protocol is intended for the adult population and mandates that the dose be accurately measured from the oral solution. The specific constraints on duration reflect the standard approach for this class of centrally acting anti-obesity agents, ensuring treatment is highly focused and time-bound. The administration is conditional on the simultaneous implementation of the required lifestyle interventions, as specified in the prescribing information.

Official Step Sequence

• The prescriber determines the individualized daily dose of Cathine hydrochloride.
• The patient takes the measured dose of the oral solution once daily in the morning.
• The course of treatment must cease by the maximum established duration of 24 weeks.

ALVALIN: Recent Clinical Evidence

Evidence for Use in Adjunct Treatment for Diet-Related Obesity

Clinical trials evaluated the investigational use of ALVALIN in adults with obesity who are participating in a structured weight loss program. Research examined multicenter, controlled trials that randomly assigned participants to an active compound group or a placebo group. These studies was observed in a defined time interval to research exploring short-term symptom changes related to appetite.

Study Design and Measured Outcomes

The primary outcomes studied in the main trials included the absolute change in body weight measured in kilograms, and the percentage of initial body weight change over the study period. Studies also monitored secondary outcomes related to systemic or functional imbalance, such as changes in the Body Mass Index (BMI). When comparing the groups, findings describe patterns observed in the studies related to change in body weight in participants receiving the active compound compared to those receiving a placebo.

Long-Term Studies and Follow-Up Data

The key clinical trials for ALVALIN studies explored outcomes primarily over intermediate-term follow-up periods, commonly spanning up to 24 weeks. However, existing studies provide research provides insight into short-term changes only, as follow-up durations were limited. This means certainty remains low regarding long-term clinical patterns, and there is limited information for long-term outcomes, such as the sustained change in Body Mass Index (BMI) beyond the study timeframe.

What is Still Uncertain About the Evidence for ALVALIN

Based on the evidence reviewed, the overall evidence level is moderate. This reflects that while recent, well-designed placebo-controlled trials have been conducted, the overall body of human data is considered limited. Specifically, there are acknowledged research limitation frames regarding the length of follow-up and the certainty remains low regarding the long-term clinical trajectory. Scientific literature explicitly notes that additional clinical studies may be needed to further build the comprehensive evidence landscape.

Key Studies & References A08AA07 - ATC/DDD Index - FHI (for therapeutic classification)

Common questions about ALVALIN (FAQ)

---

Q: Is ALVALIN a controlled substance or scheduled medication?

A: Official regulatory documents generally classify the active ingredient, Cathine (D-norpseudoephedrine), as a Schedule IV controlled substance in regions that use this system. This classification is used for medicines with accepted medical uses that carry a recognized potential for abuse.

---

Q: Is there a risk of dependence or withdrawal symptoms associated with ALVALIN?

A: Regulatory agencies classify Cathine as a Schedule IV controlled substance due to a recognized potential for abuse and dependence. Due to the potential for withdrawal symptoms, cessation of the medicine requires guidance from a healthcare professional.

---

Q: Can women who are pregnant or breastfeeding use ALVALIN?

A: Official documents indicate that the use of ALVALIN during pregnancy is generally not recommended due to potential risks to the fetus. For breastfeeding, the active substance may pass into breast milk, and its use is generally not recommended to avoid potential adverse effects on the infant.

---

Q: Are there any restrictions on driving or operating machinery while taking ALVALIN?

A: Due to the potential for effects on the nervous system, such as dizziness or impaired concentration, official safety information notes the possibility of impaired ability to safely drive or operate machinery due to these effects.

---

Q: Can ALVALIN be used by individuals with type 2 diabetes?

A: Official documents state that Cathine is used with caution in patients who have pre-existing conditions such as diabetes mellitus. This caution is necessary due to the drug's classification as a sympathomimetic, which can influence certain bodily systems.

---

Q: Is it safe to take ALVALIN if I have a history of kidney problems?

A: Official information indicates that caution is necessary for this population. Clinical studies have listed pre-existing conditions such as impaired kidney function as an exclusion criterion for participation.

---

Q: Does ALVALIN have a connection to mental health side effects like mood changes?

A: The official safety profile documents Central Nervous System (CNS) effects. While anxiety is a common documented effect, general mood changes beyond this are covered under the broad classification of CNS effects and require specific review by an individual's prescriber.

---

Q: Does ALVALIN contain any ingredients that might cause an allergic reaction?

A: Official regulatory documents, such as the Summary of Product Characteristics, list both the active ingredient and the inactive components (excipients). A known hypersensitivity (allergic reaction) to any of these listed components is defined as a contraindication for use.

---

Q: Can ALVALIN be stopped suddenly, or does it require a gradual reduction?

A: Official administration guidelines set a maximum duration of use. The prescribing information for this class of drug often addresses the possibility of withdrawal symptoms, which may influence the manner in which the medicine is discontinued.

---

Q: Can ALVALIN be taken while also drinking coffee or other caffeine products?

A: Official product information notes that co-administration with other sympathomimetic agents can carry an increased risk of pressor potentiation (increased blood pressure). Caffeine, due to its stimulant effects, may be associated with potentially increasing the stimulant effects when combined with Cathine.

---

Q: Is ALVALIN safe for long-term use, or is it only for a short period?

A: Official regulatory documents state that the course of therapy for ALVALIN is strictly limited to short-term use. This defined period must not exceed 24 weeks (six months), reflecting the standard regulatory approach for this class of weight management medicine.

Storage and Handling Conditions

ALVALIN (Cathine oral solution) must be stored according to the requirements specified in the regulatory labeling to maintain its stability and effectiveness.

Storage Requirement	Official Condition
Temperature Range	Store the product at a temperature not above 25 C (77 F).
Prohibited Environment	The solution must not be stored in the refrigerator or frozen.
Container Protection	The medicine must be kept in the original container and the bottle must be kept tightly closed.
In-Use Stability	Once the bottle is opened, the solution must be used within 12 weeks (3 months).

For safety, the medication must be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired ALVALIN must not be discarded with household waste or poured into wastewater. Disposal must strictly adhere to local regulatory requirements for medicinal waste, typically by returning the product to a pharmacy or authorized collection point.